0 516

Cited 12 times in

Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases

DC Field Value Language
dc.contributor.author천재희-
dc.contributor.author박소희-
dc.date.accessioned2019-12-18T00:43:46Z-
dc.date.available2019-12-18T00:43:46Z-
dc.date.issued2019-
dc.identifier.issn0815-9319-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173196-
dc.description.abstractBACKGROUND AND AIM: Variation in medical care can be an obstacle to improving quality and outcome of treatment. We conducted a nationwide, population-based study to identify regional variations in medication prescription rates in Korean patients with inflammatory bowel diseases (IBDs). METHODS: Using the National Health Insurance claims, we collected data on patients diagnosed with IBD (8974 cases of Crohn's disease [CD] and 17 167 cases of ulcerative colitis [UC]) between 2010 and 2016. RESULTS: Overall rates of biologics (infliximab or adalimumab) use in CD and UC were 19.6% and 6.1%, respectively, and those of immunomodulator (azathioprine or 6-mercaptopurine) use were 66.9% and 20.4%, respectively. The average periods from diagnosis to first biologics use for CD and UC were 1.6 and 1.8 years, respectively, and those of immunomodulators were 0.6 and 1.3 years, respectively. In Seoul, Daegu, and Busan, three major cities in Korea, biologics prescription rates for CD were 20.7%, 22.9%, and 14.6%, respectively, and those for UC were 7.3%, 6.7%, and 4.5%, respectively. In the top 7 regions with the highest number of patients in Seoul, there were 3.6-fold and 3.2-fold variations between regions with the highest and lowest frequency of biologics use in CD and UC, respectively. In addition, there were 1.6-fold and 2.8-fold variations between regions with the highest and lowest frequency of immunomodulator use for CD and UC, respectively. CONCLUSIONS: Regional variation exists in medication prescription rates within a single city as well as nationwide, suggesting that standardization of IBD treatment is necessary in Korea.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherBlackwell Scientific Publications-
dc.relation.isPartOfJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleRegional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMinkyung Han-
dc.contributor.googleauthorYoon Suk Jung-
dc.contributor.googleauthorJae Hee Cheon-
dc.contributor.googleauthorSohee Park-
dc.identifier.doi10.1111/jgh.14609-
dc.contributor.localIdA04030-
dc.relation.journalcodeJ01417-
dc.identifier.eissn1440-1746-
dc.identifier.pmid30672608-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/jgh.14609-
dc.subject.keywordCrohn's disease-
dc.subject.keywordbiologics-
dc.subject.keywordimmunomodulator-
dc.subject.keywordinflammatory bowel disease-
dc.subject.keywordulcerative colitis-
dc.subject.keywordvariation in treatment-
dc.contributor.alternativeNameCheon, Jae Hee-
dc.contributor.affiliatedAuthor천재희-
dc.citation.volume34-
dc.citation.number7-
dc.citation.startPage1166-
dc.citation.endPage1174-
dc.identifier.bibliographicCitationJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.34(7) : 1166-1174, 2019-
dc.identifier.rimsid64104-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.